US 12,263,277 B2
Uniaxially-aligned nanofiber scaffolds and methods for producing and using same
Steven L. Goudy, Decatur, GA (US); and Edward A. Botchwey, Decatur, GA (US)
Assigned to Oridivus LLC, Decatur, GA (US)
Filed by Oridivus LLC, Decatur, GA (US)
Filed on Feb. 3, 2020, as Appl. No. 16/780,596.
Claims priority of provisional application 62/800,327, filed on Feb. 1, 2019.
Prior Publication US 2021/0001010 A1, Jan. 7, 2021
Int. Cl. A61L 27/54 (2006.01); A61K 31/137 (2006.01); A61L 27/16 (2006.01); A61L 27/36 (2006.01)
CPC A61L 27/54 (2013.01) [A61K 31/137 (2013.01); A61L 27/16 (2013.01); A61L 27/3691 (2013.01); A61L 2400/06 (2013.01); A61L 2400/12 (2013.01)] 14 Claims
OG exemplary drawing
 
1. An implantable scaffold comprising:
a plurality of nanofibers forming a flat portion having a diameter between 1 mm and 23 mm;
wherein all of the nanofibers within the plurality of nanofibers are uniaxially aligned; and
wherein each of the plurality of nanofibers comprises polycaprolactone (PCL), poly (lactic-co-glycolic-acid) (PLGA), and an S1P1 agonist;
wherein the S1P1 agonist is differentially released for controlled release with an initial burst release in the first hours, followed by a delay, and a second phase of release occurring between 3 and 5 days following implantation;
wherein the plurality of nanofibers is configured to release between 93.87% and 94.78% of the S1P1 agonist within the first 24 hours following implantation;
wherein the plurality of nanofibers is configured to release about 96.7% of the S1P1 agonist after about 75 hours following implantation; and
wherein the S1P1 agonist is FTY720.